Results: Lf immunostaining, with variable ID scores, was encountered in 11/25 (44 %) metastatic bone lesions. Immunoreactivity for Lf was found in primary carcinomas with a percentage of neoplastic cells ranging between 50 tand 75 %, although this positivity decreased in breast carcinomas (37.5 %) and was totally absent in lung cancers.